Home » Clinical Trials » Leukemia » NCT05943314
NCT05943314

Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in Refractory/Recurrent Acute Myeloid Leukemia: a Single-arm, Non-blind Clinical Study

Study Summary

This is a single-center, single-arm, open, intravenous drug administration of the safety and efficacy of clinical study.

Interested in this trial?

Submit an Inquiry

Interventions

CLL1/+CD33 CAR-TBIOLOGICAL
CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.

Study Locations

FacilityCityStateCountry
Fujian Provincial Children's HospitalFuzhouFujianChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026